Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 2,034 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Bristol-Myers Squibb Clear all
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

NCT02273960
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
BMS-986004 75 mg IV, BMS-986004 225 mg IV, BMS-986004 675 mg IV, BMS-986004 1500 mg IV
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 16, 2026, 2:57 AM EDT
Recruiting Phase 2 Interventional

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

NCT04933903
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Ipilimumab, Nivolumab, SBRT
Drug · Radiation
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

NCT06715683
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986278 Batched method, Dose A, BMS-986278 Batched method, Dose B, BMS-986278 Continuous method
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

NCT02227459
View directory record Official record
Conditions
Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)
Interventions
ND-L02-s0201 Injection
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 16, 2026, 2:57 AM EDT
Terminated Phase 2 Interventional Results available

Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer

NCT00203931
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Cetuximab, Pemetrexed
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy

NCT00336856
View directory record Official record
Conditions
Colon Cancer, Rectum Cancer
Interventions
Cetuximab, Irinotecan
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer

NCT00744497
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Placebo, Dasatinib, Docetaxel, Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
43
States / cities
Mobile, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 3 Interventional

Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

NCT00002224
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin

NCT00420186
View directory record Official record
Conditions
Cancer (Solid Tumors)
Interventions
BMS-690514
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Buffalo, New York • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

NCT00365339
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir+Ritonavir+Tenofovir, Atazanavir+Ritonavir+Tenofovir+Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2011 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Aripiprazole (Abilify) in Children With Symptoms of Mania

NCT00194077
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
4 Years to 9 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Oct 16, 2026, 2:57 AM EDT
Withdrawn Phase 2 Interventional

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

NCT06180863
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
oral azacitidine (CC-486)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

NCT00101647
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
21
States / cities
Birmingham, Alabama • Anaheim, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

NCT02897765
View directory record Official record
Conditions
Urinary Bladder Cancer, Bladder Tumors, Transitional Cell Carcinoma of the Bladder, Malignant Melanoma, Melanoma, Skin Cancer, Carcinoma, Non-Small-Cell Lung, Lung Cancer
Interventions
NEO-PV-01, Nivolumab, Adjuvant
Biological · Other
Lead sponsor
BioNTech US Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo

NCT03421652
View directory record Official record
Conditions
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Nivolumab, Radiation
Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Detroit, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators

NCT00162448
View directory record Official record
Conditions
Heart Diseases
Interventions
BMS-394136, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Salisbury, Maryland • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2008 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01498978
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
ipilimumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
New Brunswick, New Jersey • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 3 Interventional

A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control

NCT00246987
View directory record Official record
Conditions
Diabetes, Type 2
Interventions
Muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
82
States / cities
Anniston, Alabama • Birmingham, Alabama • Haleyville, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 16, 2026, 2:57 AM EDT
Active, not recruiting Phase 1 Interventional

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

NCT04658147
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Relatlimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 16, 2026, 2:57 AM EDT
Completed No phase listed Observational

Mavacamten in Obstructive Hypertrophic Cardiomyopathy

NCT07168655
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Abatacept Versus Adalimumab Head-to-Head

NCT00929864
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Adalimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
869 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
63
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Not applicable Interventional

A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

NCT00002293
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Nystatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Birmingham, Alabama • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

NCT05302921
View directory record Official record
Conditions
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Melanoma, Hepatoblastoma, Hepatocellular Carcinoma, Neuroblastoma, Wilms Tumor
Interventions
Cryoablation Therapy, Nivolumab, Ipilimumab
Procedure · Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 39 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 16, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants

NCT05304533
View directory record Official record
Conditions
Healthy Participants
Interventions
MYK-224, Itraconazole, Verapamil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 16, 2026, 2:57 AM EDT